Literature DB >> 22387368

Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Yunqi Xu1, Junqiang Yan, Peng Zhou, Jiejie Li, Huimin Gao, Ying Xia, Qing Wang.   

Abstract

Cognitive dysfunction is one of the most typical characteristics in various neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease (advanced stage). Although several mechanisms like neuronal apoptosis and inflammatory responses have been recognized to be involved in the pathogenesis of cognitive dysfunction in these diseases, recent studies on neurodegeneration and cognitive dysfunction have demonstrated a significant impact of receptor modulation on cognitive changes. The pathological alterations in various receptors appear to contribute to cognitive impairment and/or deterioration with correlation to diversified mechanisms. This article recapitulates the present understandings and concepts underlying the modulation of different receptors in human beings and various experimental models of Alzheimer's disease and Parkinson's disease as well as a conceptual update on the underlying mechanisms. Specific roles of serotonin, adrenaline, acetylcholine, dopamine receptors, and N-methyl-D-aspartate receptors in Alzheimer's disease and Parkinson's disease will be interactively discussed. Complex mechanisms involved in their signaling pathways in the cognitive dysfunction associated with the neurodegenerative diseases will also be addressed. Substantial evidence has suggested that those receptors are crucial neuroregulators contributing to cognitive pathology and complicated correlations exist between those receptors and the expression of cognitive capacities. The pathological alterations in the receptors would, therefore, contribute to cognitive impairments and/or deterioration in Alzheimer's disease and Parkinson's disease. Future research may shed light on new clues for the treatment of cognitive dysfunction in neurodegenerative diseases by targeting specific alterations in these receptors and their signal transduction pathways in the frontal-striatal, fronto-striato-thalamic, and mesolimbic circuitries.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22387368      PMCID: PMC3371373          DOI: 10.1016/j.pneurobio.2012.02.002

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  184 in total

1.  Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography.

Authors:  Balázs Gulyás; Elena Pavlova; Péter Kása; Károly Gulya; Lidia Bakota; Szilvia Várszegi; Eva Keller; Mónika Csilla Horváth; Sangram Nag; István Hermecz; Kálmán Magyar; Christer Halldin
Journal:  Neurochem Int       Date:  2010-11-12       Impact factor: 3.921

2.  Chronic treatment with simvastatin upregulates muscarinic M1/4 receptor binding in the rat brain.

Authors:  Q Wang; A Zengin; W Ying; K A Newell; P Wang; W Yeo; P T-H Wong; M A Yenari; X-F Huang
Journal:  Neuroscience       Date:  2008-04-23       Impact factor: 3.590

Review 3.  Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: potential targets for the development of new therapeutic agents.

Authors:  Roberta J Ward; Frédéric Lallemand; Philippe de Witte; David T Dexter
Journal:  Prog Neurobiol       Date:  2008-04-04       Impact factor: 11.685

Review 4.  What has been learnt from study of dopamine receptors in Parkinson's disease?

Authors:  M J Hurley; P Jenner
Journal:  Pharmacol Ther       Date:  2006-02-03       Impact factor: 12.310

5.  [Acetylcholine receptors (author's transl)].

Authors:  G Kato; Y Agid
Journal:  Nouv Presse Med       Date:  1979-06-30

6.  Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer's disease.

Authors:  Yasuhiro Tanaka; Kenichi Meguro; Satoshi Yamaguchi; Hiroshi Ishii; Shoichi Watanuki; Yoshihito Funaki; Keiichiro Yamaguchi; Atsushi Yamadori; Ren Iwata; Masatoshi Itoh
Journal:  Ann Nucl Med       Date:  2003-10       Impact factor: 2.668

7.  Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease.

Authors:  N Kemppainen; M Laine; M P Laakso; V Kaasinen; K Någren; T Vahlberg; T Kurki; J O Rinne
Journal:  Eur J Neurosci       Date:  2003-07       Impact factor: 3.386

8.  A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation.

Authors:  M Ruat; E Traiffort; J M Arrang; J Tardivel-Lacombe; J Diaz; R Leurs; J C Schwartz
Journal:  Biochem Biophys Res Commun       Date:  1993-05-28       Impact factor: 3.575

9.  Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory.

Authors:  Fumihiko Yasuno; Tetsuya Suhara; Takashi Nakayama; Tetsuya Ichimiya; Yoshiro Okubo; Akihiro Takano; Tomomichi Ando; Makoto Inoue; Jun Maeda; Kazutoshi Suzuki
Journal:  Am J Psychiatry       Date:  2003-02       Impact factor: 18.112

Review 10.  Rationale for and use of NMDA receptor antagonists in Parkinson's disease.

Authors:  Penelope J Hallett; David G Standaert
Journal:  Pharmacol Ther       Date:  2004-05       Impact factor: 12.310

View more
  74 in total

1.  Signaling pathways involved in 1-octen-3-ol-mediated neurotoxicity in Drosophila melanogaster: implication in Parkinson’s disease.

Authors:  Arati A Inamdar; Prakash Masurekar; Muhammad Hossain; Jason R Richardson; Joan W Bennett
Journal:  Neurotox Res       Date:  2014-02       Impact factor: 3.911

2.  Drotaverine Inhibitor of PDE4: Reverses the Streptozotocin Induced Alzheimer's Disease in Mice.

Authors:  Samra Nazir; Fareeha Anwar; Uzma Saleem; Bashir Ahmad; Zohaib Raza; Maham Sanawar; Artta Ur Rehman; Tariq Ismail
Journal:  Neurochem Res       Date:  2021-04-20       Impact factor: 3.996

3.  The Functional Activity of the Human Serotonin 5-HT1A Receptor Is Controlled by Lipid Bilayer Composition.

Authors:  M Gertrude Gutierrez; Kylee S Mansfield; Noah Malmstadt
Journal:  Biophys J       Date:  2016-06-07       Impact factor: 4.033

4.  Exploration of the Acetylcholinesterase Inhibitory Activity of Some Alkaloids from Amaryllidaceae Family by Molecular Docking In Silico.

Authors:  Willian O Castillo-Ordóñez; Elvira R Tamarozzi; Gabriel M da Silva; Andrés F Aristizabal-Pachón; Elza T Sakamoto-Hojo; Catarina S Takahashi; Silvana Giuliatti
Journal:  Neurochem Res       Date:  2017-05-11       Impact factor: 3.996

Review 5.  Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.

Authors:  Briana J Davie; Arthur Christopoulos; Peter J Scammells
Journal:  ACS Chem Neurosci       Date:  2013-05-23       Impact factor: 4.418

Review 6.  Serotonergic system, cognition, and BPSD in Alzheimer's disease.

Authors:  Saikat Chakraborty; Jack C Lennon; Sridhar A Malkaram; Yan Zeng; Daniel W Fisher; Hongxin Dong
Journal:  Neurosci Lett       Date:  2019-04-01       Impact factor: 3.046

7.  Neuroprotective efficiency of Mangifera indica leaves extract on cadmium-induced cortical damage in rats.

Authors:  Naif E Al Omairi; Omyma K Radwan; Yahea A Alzahrani; Rami B Kassab
Journal:  Metab Brain Dis       Date:  2018-03-20       Impact factor: 3.584

Review 8.  Alzheimer's Disease Therapeutic Approaches.

Authors:  Maria Revi
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 9.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.

Authors:  Ravi Rajmohan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

10.  Low Cerebral Glucose Metabolism: A Potential Predictor for the Severity of Vascular Parkinsonism and Parkinson's Disease.

Authors:  Yunqi Xu; Xiaobo Wei; Xu Liu; Jinchi Liao; Jiaping Lin; Cansheng Zhu; Xiaochun Meng; Dongsi Xie; Dongman Chao; Albert J Fenoy; Muhua Cheng; Beisha Tang; Zhuohua Zhang; Ying Xia; Qing Wang
Journal:  Aging Dis       Date:  2015-11-17       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.